Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case–control study
- 15 January 2015
- journal article
- Published by Springer Science and Business Media LLC in Journal of Assisted Reproduction and Genetics
- Vol. 32 (3), 429-434
- https://doi.org/10.1007/s10815-014-0426-6
Abstract
To investigate efficacy and safety of a controlled ovarian stimulation (COS) protocol in which a single dose of Corifollitropin-alfa (CFα) was administered on day 4 of a GnRH-antagonist cycle. Cohort case–control study. University Hospital. One hundred twenty-two normally cycling women expected to be normal responders to COS. In 61 patients, CFα (100–150 μg) was injected subcutaneously on day 4 of a spontaneous menstrual cycle; a GnRH-antagonist was added from day 8 (fixed protocol; 0.25 mg/day). If needed to complete follicular maturation, recombinant FSH (rFSH) daily injections (150/200 IU/day) were given from day 11. A control group of 61 matched women was stimulated with daily subcutaneous injections of rFSH (100–150 U/day) from day 4 of the cycle, and received GnRH-antagonist (0.25 mg/day) from day 8. IVF or ICSI was performed according to the sperm characteristics, and 1–2 embryos were transferred in utero under US guidance on day 2. Number of retrieved cumulus-oocyte complexes (COCs), clinical pregnancy rate (PR), implantation rate (IR), ongoing PR at 10 weeks, number of injections/cycle, ovarian hyperstimulation syndrome (OHSS) rate. No cycle was cancelled and the mean number of retrieved COCs was comparable in patients and controls. About 60 % of CF-alfa treated women had no need of daily rFSH addition, and the mean number of injections/cycle was significantly lower in the CF-alfa group than in controls (p CFα may be started on day 4 of the cycle obtaining results comparable to those of a COS using day 4-start daily rFSH, with significantly less injections and a similar risk of OHSS.Keywords
This publication has 28 references indexed in Scilit:
- Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin αReproductive BioMedicine Online, 2013
- Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot studyFertility and Sterility, 2013
- MILD ovarian stimulation with GnRH-antagonist vs. long protocol with low dose FSH for non-PCO high responders undergoing IVF: a prospective, randomized study including thawing cyclesJournal of Assisted Reproduction and Genetics, 2012
- Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSHReproductive BioMedicine Online, 2012
- Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicityHuman Reproduction, 2011
- Milder is better? advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilizationReproductive Biology and Endocrinology, 2011
- Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight womenReproductive BioMedicine Online, 2010
- A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocolHuman Reproduction, 2009
- Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequencyHuman Reproduction Update, 2009
- Mild ovarian stimulation for IVFHuman Reproduction Update, 2008